Uso do concentrado de plaquetas em doença da superfície ocular

Abstract

RESUMOApós uma injúria corneana, é fundamental a eliminação dos miofibroblastos a fim de garantir sua transparência. Os miofibroblastos corneanos apresentam um receptor para o fator ativador de plaquetas em sua superfície. O concentrado de plaquetas é uma das mais ricas fontes de fatores de crescimento essenciais, causando redução do sangramento, da inflamação, da escarificação, do tempo de cicatrização, acelerando assim o fechamento das úlceras.Relatamos um caso de úlcera trófica corneana não responsiva aos tratamentos convencionais e que apresentou melhora clínica significativa com colírio de concentrado de plaquetas autólogo.Descritores: Plaquetas; Preservação de sangue; Ceratoplastia penetrante, Oftalmopatias; Relato de casos [Tipo de publicação]

The Use of Platelet-Rich Plasma in Dry Eye Disease

“…Sodium citrate can be used as an anticoagulant in the ratio of 1 to every 9 ml of whole blood processed. In 2 cycles, 72 ml of platelet concentrate was collected; the hematimetric indices of the patient and also the platelet concentrate indices are evaluated before and after the procedure (Coulter AcT Diff) [81]. Platelet growth factors were generally obtained in a ranked room; hence, the handling of platelet concentrate was performed within a Category II-Type A biological safety cabinet.…”

“…The release of serum with platelet growth factors in the study by Rezende et al was done as follows: weekly, thawed Falcon tube containing approximately 10 ml of autologous serum with platelet growth factors that was transferred to flasks, and the patient is advised to keep the biological medicine at a temperature below −10°C (freezer) and to unfreeze it naturally immediately before each use [81].…”

“…PRP has been reported in corneal ulcers [80][81][82], in chemical burns [83,84], in restoration of lacrimal function [85], in blepharoplasties surgeries [86], in ocular surface syndrome after refractive surgeries [44], and in graft-versus-host disease [87].…”